BIOGEN IDEC (IDP MU) stock market data APIs
€111.0923
0(0%)
as of July 8, 2025
Try our APIs with
free plan!
BIOGEN IDEC Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for IDP.MU.
Prev. Close
111.0923
Open
111.0923
High
111.0923
Low
111.0923
52 wk Range
99.02-217
Market Cap
30 257 M
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BIOGEN IDEC data using free add-ons & libraries
Get BIOGEN IDEC Fundamental Data
BIOGEN IDEC Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BIOGEN IDEC News
New
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
Ionis Pharmaceuticals (IONS) shares ended the last trading session 9.1% higher at $43.59. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the sessio...
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
Biogen BIIB initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data readout i...
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
Over the past six months, Biogen’s stock price fell to $125.58. Shareholders have lost 16.3% of their capital, which is disappointing considering the S&P 500 has climbed by 5.7%. This might have inv...
AbbVie to buy Capstan Therapeutics for up to $2.1 billion
(Reuters) -U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion. Capstan develops CAR-T therapies, a type of treatm...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
